Antiretroviral resistance during successful therapy of HIV type 1 infection.
about
Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of actionImpaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjectsDynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencingDigoxin suppresses HIV-1 replication by altering viral RNA processingConstruction of a human immunodeficiency virus type 1 (HIV-1) library containing random combinations of amino acid substitutions in the HIV-1 protease due to resistance by protease inhibitors.Experimental evolution of an emerging plant virus in host genotypes that differ in their susceptibility to infection.Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication.Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy.A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.Genetically modified immunocompetent cells in HIV infection.Molecular basis of adaptive convergence in experimental populations of RNA viruses.The application of molecular phylogenetics to the analysis of viral genome diversity and evolution.Frequent intra-subtype recombination among HIV-1 circulating in TanzaniaA novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides.Evolution of drug-resistant viral populations during interruption of antiretroviral therapyClinical management of HIV drug resistance.Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapyTempo and mode of plant RNA virus escape from RNA interference-mediated resistanceLatently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activityExperimental analysis of sources of error in evolutionary studies based on Roche/454 pyrosequencing of viral genomes.Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.Toward the development of a single-round infection assay based on EGFP reporting for anti-HIV-1 drug discovery.Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child.Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.Characterization of novel inhibitors of HIV-1 replication that function via alteration of viral RNA processing and rev functionModeling HIV persistence, the latent reservoir, and viral blips.Exploration of Phytochemicals Found in Terminalia sp. and their Antiretroviral Activities
P2860
Q24316120-8669DB01-607E-4217-BED2-C349EE37BF54Q24534863-7F89F7CF-9F4B-4D63-A0D6-03ABAE584B08Q24798701-74403012-BA08-4DA5-A567-047B4C6E91E9Q28474783-0DD87CD7-8178-46C9-B1FE-16F6F15D54F6Q28489086-96ABFEA2-0BC9-47EC-B567-E9E38EDA57C0Q30818137-30ED4F8F-9421-4A9D-AE39-9D823AA6DD9DQ31162373-A1B73914-D775-45D4-86FB-D9295159AF85Q33589167-21186E15-95A9-42C3-B0E4-BE43E2908BD3Q33622741-60523A45-7708-40A5-8053-D6D91CA23738Q33724247-31CD4FCB-291F-4415-8BDC-1D36C9AB4DA4Q33807628-D811AEE5-DF96-456D-9796-5FE386008086Q33851627-4185BF11-0148-4C6E-8C3A-56E04FA8A4C7Q33892114-1B8D0304-3DDA-4E46-8A82-207804D77E64Q33906239-048EB85B-554E-47D6-837D-45854A90C517Q33952995-F65F84FF-9501-49F8-BC46-AB5457F402ACQ34028490-F8C91903-DA86-41F3-9070-D62DC65CA214Q34326482-2170F787-A245-400F-867F-5F4992948141Q34345655-FA3F402E-689A-4DAD-87C2-E0548D1082EFQ34473072-A0516A08-92B0-4C6E-B7C2-49F9F659FC3DQ34564279-79CDB811-B41C-4B03-8107-C70BC947CE91Q34616146-61254EC0-4A23-43D7-9484-85BD62586A93Q34747515-DE004E17-457F-4F5E-B5CC-1F470BB678EFQ34936859-8CFF2CCB-8C96-4A69-83CB-1211D2E7EBF0Q35052661-5D5D2471-1575-4CA0-A866-7A0BFCA8CEADQ35077423-AE0B76C3-5F65-4242-B6F7-AFCA4C920DF7Q35261045-94CEB608-7CE7-4C91-925A-84741BF78D80Q35264750-100CF9A1-7761-4F83-9F01-3BB4D2EF654DQ35383202-D2EC60DA-8F54-4405-924B-F8A279064FC5Q35761152-A269EE2B-B77A-4C68-870A-5DB66112BB91Q35930289-C4D6C0B2-3505-4879-804D-6F2777C0767EQ35943417-3F1CFA94-A169-415A-A95C-DEA88CD7DA9AQ36102538-025F7C1A-249F-4554-B60F-7B6E4B387AC0Q36589574-CFC755A1-BCC2-4167-8204-34B879F08486Q36684112-6689AB5E-31DC-4EA9-A361-8BC4C603B465Q37156918-AFE10E8A-8186-4753-B982-3EEFB1F4CC9EQ37175647-2F96A475-0B05-457A-88E5-079D6676E8F5Q37184391-4536E979-61A5-4769-A4E3-DC972961E946Q37271140-5803F575-6591-47B0-9F85-593AE28081E1Q37365718-58BDAB2E-A701-4557-B39F-4A92B1B0778CQ37558695-3E9B5226-1952-4789-84B7-589767883308
P2860
Antiretroviral resistance during successful therapy of HIV type 1 infection.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antiretroviral resistance during successful therapy of HIV type 1 infection.
@ast
Antiretroviral resistance during successful therapy of HIV type 1 infection.
@en
type
label
Antiretroviral resistance during successful therapy of HIV type 1 infection.
@ast
Antiretroviral resistance during successful therapy of HIV type 1 infection.
@en
prefLabel
Antiretroviral resistance during successful therapy of HIV type 1 infection.
@ast
Antiretroviral resistance during successful therapy of HIV type 1 infection.
@en
P2093
P2860
P356
P1476
Antiretroviral resistance during successful therapy of HIV type 1 infection
@en
P2093
B D Walker
C J Petropoulos
D D Richman
E Rosenberg
M P DePasquale
P2860
P304
10948-10953
P356
10.1073/PNAS.97.20.10948
P407
P577
2000-09-01T00:00:00Z